B
BDTX
Black Diamond Therapeutics, Inc.
1.700
+0.020+1.19%Pre Market: 1.710 +0.010 +0.59%04:00 10/15 EDT
OPEN/PREV CLOSE1.670/1.680
TODAY RANGE1.630-1.760
VOL1
MARKET CAP97.67M
52 WEEK RANGE1.600-4.940
AVG VOL (3M)619.95K
% TURNOVER1.65%
TURNOVER0
P/E (TTM)-2.2825
% RANGE7.74%
EPS(TTM)-0.7448
P/E(FORWARD)-2.7586
P/B1.016
BVPS1.673
DIVIDEND--
P/S1.388
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP96.58M
SHARES OUTSTANDING57.45M
NEXT EARNINGS11/04-11/09
FREE FLOAT56.81M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/06 13:56
Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2
TipRanks·08/06 13:18
Black Diamond Therapeutics setup ‘attractive,’ says Jefferies
Seeking Alpha·08/05 21:54
Black Diamond Therapeutics GAAP EPS of -$0.17 beats by $0.03
Benzinga·08/05 20:39
Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate
TipRanks·08/05 20:21
Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)
Dow Jones·08/05 20:01
*Black Diamond Theraptcs 2Q Loss/Shr 17c >BDTX
Dow Jones·08/05 20:01
Press Release: Black Diamond Therapeutics Reports -2-
Seeking Alpha·07/06 05:51
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Simply Wall St·07/01 10:43
Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth
TipRanks·06/29 20:52
Black Diamond Shareholders Approve Directors and Annual Say-on-Pay
TipRanks·06/01 13:35
Wedbush Remains a Buy on Black Diamond Therapeutics (BDTX)
NASDAQ·05/27 15:16
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
NASDAQ·05/27 15:13
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Same Industry
Name/Symbol
Change%
Price